Overview
McDermott Will & Emery has advised AUROBAC THERAPEUTICS, a biopharmaceutical company founded by Boehringer Ingelheim, bioMérieux and Evotec, on its new collaboration and licensing agreement on a Boehringer Ingelheim compound that will be developed as ATX101 for the treatment of septic shock.
Building on promising preclinical data, AUROBAC THERAPEUTICS plans to take ATX101 into clinical development in 2025.
The McDermott team that advised AUROBAC THERAPEUTICS comprised Emmanuelle Trombe, Anne-France Moreau (partners) and Amel El Mouttaki (associate).
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
